PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors

Condition(s) targeted: Dilated Cardiomyopathy

Intervention: perindopril (Drug); placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Institut National de la Santé Et de la Recherche Médicale, France

Official(s) and/or principal investigator(s):
PHILIPPE CHARRON, Principal Investigator, Affiliation: PITIE SALPETRIERE HOSPITAL, PARIS, FRANCE

This is a multicentre European double-blind,randomized and controlled trial with 2 parallel groups (1 study medication, 1 placebo) in order to analyse the impact of ACE inhibitors (ACEi) in subjects who carry a mutation but have not yet developed DCM (dilated cardiomyopathy).

Objective of the trial: Study the impact of ACE inhibitors (ACEi) in subjects who carry a mutation (leading to a genetic form of heart failure) but have not yet developed DCM.

Context. Dilated Cardiomyopathy (DCM) is one of the leading causes of Heart Failure due to systolic dysfunction and at least 30% of DCM are of familial/genetic origin, usually with autosomal dominant inheritance, and underlying genes and mutations are increasingly identified. Familial Dilated Cardiomyopathy (fDCM) is characterized by age-related penetrance (or delayed-onset), that means that the cardiac expression of the disease (echocardiographic abnormalities) is usually absent for a long period and progressively appears with advanced age, usually after 20 years of age

Hypothesis : ACEi may delay or prevent the occurrence of DCM in these subjects (pre-clinical stage).

Expected results: If the hypothesis is confirmed, and as a consequence, the knowledge derived from basic research (genes identification in DCM) will be translated into clinical practice (early identification of subjects at high risk of developing heart failure through predictive genetic testing) with the development of new therapeutic management (early ACEi) that will help to decrease the morbidity and mortality associated with the disease. This will constitute a paradigm of the development of preventive medicine thanks to the development of genetics in the cardiovascular field.

Subjects who are concerned are ≥18 years of age and ≤60 years, carry a mutation responsible for DCM and are at a preclinical stage of the disease. Total duration of treatment (perindopril versus placebo) is 3 years. A total number of 200 participants will be enrolled (100 in each group) in 7 centres.

Official title: Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Change in left ventricle diameter / volume / ejection fraction

Secondary outcome:

Echocardiographic deterioration of LVEDD or Ejection fraction

MRI - deterioration of LVEDVol or Ejection fraction

Occurence of DCM (Echo: EF< 45% and LVEDD>112%, ref Mahon, 2005)

Deterioration of other Echocardiographic parameters

Deterioration of hormonal biomarkers in serum

Clinical end-point

Clinical end-point: death

Detailed description: This study is part of a broader research program, "INHERITANCE" (INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe) research project, submitted to EU (FP7 European Union, HEALTH-2009-2. 4.2-3: Translation of basic knowledge on inherited cardiomyopathies into clinical practice) and accepted in 2009 (Grant agreement n° 241924, global coordinator: Pr Eloisa Arbustini, Pavia, Italy).

- Precardia / clinical trial Principal Investigator: Dr Philippe Charron, Pitié

Salpêtrière hospital, France

- FP7 Global Inheritance network coordinator: Pr Eloisa Arbustini, Italia

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age: ≥18 years and ≤60 years

- At least one family member should have a clinical diagnosis of dilated cardiomyopathy

(LVEF<45% and LVEDD>112%)and should not be considered as the burn-out phase of another cardiomyopathy (such as HCM, ARVC). LV noncompaction may co-exist with DCM in this patient. NB: in a patient with a mutation in LMNA gene, LVEDD may be normal whereas EF is markedly reduced, so that only a reduced LVEF is mandatory(LVEF<45%).

- Carriers of the mutation that has been identified in the family as associated with

DCM, and who have received appropriate genetic counselling before and after the announcement of the genetic result. The mutation within the family should be considered as disease-causing.

- No obvious DCM as assessed by diagnostic criteria indicated elsewhere on

echocardiography (WHO & Mestroni et al. 1999 and Mahon et al. 2005: references 3 and 9): LVEF <45% and enlarged LVEDD (>112% of predicted value according to age,BSA).

- Presence of minor LV abnormality:

- isolated LVEDD > 112% (Henry Formula)

- or reduced systolic dysfunction: 45% < LVEF < 55%, as assessed on

echocardiography.

- Able to provide informed consent, and signed informed consent.

- Able to understand and accept the study constraints

- For some European countries (such as France and Spain): participants (by themselves)

should have medical health care coverage to be included in a research study

Exclusion Criteria:

- Other disease or factor that can cause minor LV abnormalities, such as cardiotoxic

treatment or significant blood hypertension (with uncontrolled blood pressure or significant hypertrophy on echocardiography).

- Contraindication to ACE inhibitor

- Participants who are already treated with ACE inhibitor, sartan or aldosterone

receptor antagonists (for various reason such as arterial hypertension) can not be included in this study, unless they have been off these drugs for a period of 6 weeks before inclusion.

- Impaired renal function: estimated Glomerular Filtration Rate (eGFR), using MDRD

formula, < 60 ml/mn/1. 73m2.

- Baseline serum potassium >5. 5 mmol/L.

- Pregnant, parturient or breastfeeding woman or woman of childbearing potential not

under effective contraception or planned pregnancy.

- Participation in another therapeutic trial in the previous 3 months

- Participants treated with lithium

- Participant under legal guardianship

Skejby University Hospital SUH, Aarhus Universit Hospital, Aarhus 8200, Denmark; Not yet recruiting
Jens Mogensen, MD, Phone: +45 89496199, Email: jens.mogensen@dadlnet.dk
Jens MOGENSEN, MD, Principal Investigator

Pitié Salpêtrière Hospital, Paris 75013, France; Recruiting
Philippe CHARRON, MD-PhD, Phone: +33 (0)1 42 16 13 47, Email: philippe.charron@psl.aphp.fr
Philippe CHARRON, MD-PhD, Principal Investigator

University of Heidelberg UKLHD, Heidelberg 69120, Germany; Not yet recruiting
Hugo KATUS, Pr, Phone: +49-6221-56-8670, Email: hugo.katus@med.uni-heidelberg.de
Hugo KATUS, Pr, Principal Investigator

Academic Hospital IRCCS Foundation Policlinico San Matteo (OSM), Pavia 27100, Italy; Not yet recruiting
Eloisa ARBUSTINI, Pr, Phone: +39 0382 501893, Email: e.arbustini@smatteo.pv.it
Eloisa ARBUSTINI, Pr, Principal Investigator

Academisch Medisch Centrum AMC and InterUniversity Institute AMC/ICIN, Amsterdam 1105 AZ, Netherlands; Not yet recruiting
Yigal PINTO, MD, Phone: +31-20-5664927, Email: y.pinto@amc.uva.nl
Yigal PINTO, MD, Principal Investigator

Health in Code SL (SME) - Hospital Marítimo de Oza., A Coruña 15006, Spain; Not yet recruiting
Lorenzo MONSERRAT, MD, Phone: +34 981167000, Ext: 5929, Email: lorenzo.monserrat@healthincode.com
Lorenzo MONSERRAT, MD, Principal Investigator

The Heart Hospital, University College London NHS Foundation Trust, London W1G 8PH, United Kingdom; Not yet recruiting
Perry ELLIOTT, MD, Phone: +44-20-7573 8888, Email: perry.elliott@ucl.ac.uk
Perry ELLIOTT, MD, Principal Investigator

Precardia study is part of global european project INHERITANCE

Starting date: December 2011
Last updated: April 19, 2012